Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network
Xiaochao Tan, … , Ignacio I. Wistuba, Jonathan M. Kurie
Xiaochao Tan, … , Ignacio I. Wistuba, Jonathan M. Kurie
Published January 11, 2018
Citation Information: J Clin Invest. 2018;128(4):1267-1282. https://doi.org/10.1172/JCI97225.
View: Text | PDF | Erratum
Research Article Oncology

The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network

  • Text
  • PDF
Abstract

Epithelial tumor cells undergo epithelial-to-mesenchymal transition (EMT) to gain metastatic activity. Competing endogenous RNAs (ceRNAs) have binding sites for a common set of microRNAs (miRs) and regulate each other’s expression by sponging miRs. Here, we address whether ceRNAs govern metastasis driven by the EMT-activating transcription factor ZEB1. High miR-181b levels were correlated with an improved prognosis in human lung adenocarcinomas, and metastatic tumor cell lines derived from a murine lung adenocarcinoma model in which metastasis is ZEB1-driven were enriched in miR-181b targets. ZEB1 relieved a strong basal repression of α1 integrin (ITGA1) mRNA, which in turn upregulated adenylyl cyclase 9 mRNA (ADCY9) by sponging miR181b. Ectopic expression of the ITGA1 3′-untranslated region reversed miR-181b–mediated metastasis suppression and increased the levels of adenylyl cyclase 9 protein (AC9), which promoted tumor cell migration and metastasis. In human lung adenocarcinomas, ITGA1 and ADCY9 levels were positively correlated, and an AC9-activated transcriptomic signature had poor-prognostic value. Thus, ZEB1 initiates a miR-181b–regulated ceRNA network to drive metastasis.

Authors

Xiaochao Tan, Priyam Banerjee, Xin Liu, Jiang Yu, Don L. Gibbons, Ping Wu, Kenneth L. Scott, Lixia Diao, Xiaofeng Zheng, Jing Wang, Ali Jalali, Milind Suraokar, Junya Fujimoto, Carmen Behrens, Xiuping Liu, Chang-gong Liu, Chad J. Creighton, Ignacio I. Wistuba, Jonathan M. Kurie

×

Figure 1

miRs not repressed by ZEB1 have metastasis suppressor activity.

Options: View larger image (or click on image) Download as PowerPoint
miRs not repressed by ZEB1 have metastasis suppressor activity.
(A) Quan...
(A) Quantitative reverse transcription PCR (qPCR) analysis of miRs in 393P_ZEB1 cells (ZEB1) and 393P_vector cells (Vec). Results expressed relative to 393P_vector cells. miR-200b included as positive control. (B) Enrichment of ZEB1-upregulated genes in miR targets as assessed by a hypergeometric test. (C) qPCR assays quantify antagomir-mediated depletion of miRs in 393P cells. Results expressed relative to control antagomirs (anti-NC). (D) Boyden chamber assays on antagomir- and control-transfected cells. Migratory and invasive cells were photographed (images) and counted (bar graph). Scale bar: 200 μm. (E) Relative densities of transfectants on plastic. (F) Primary tumor weights (left) and numbers of lung metastases (right) in mice injected subcutaneously with 344SQ cells that express ectopic miR-181b or vector (Vec). (G) Fluorescence microscopic images of lung metastases in mice injected by tail vein with red fluorescent protein–labeled (RFP-labeled) 344SQ cells transfected with miR-181b or control mimics. Scatter plot: numbers of lung metastases per mouse (dots). (H) Numbers of viable 344SQ and H1299 transfectants on low-adhesion plates. n = 4. (I) Western analysis detects cleaved PARP as a marker of apoptosis in transfectants on adhesive or low-adhesion (suspension) plates. β-Actin is loading control. (J) Soft agar colony formation by miR-181b and vector control (Vec) transfectants. Colonies were photographed (images) and counted (bar graphs). Scale bar: 100 μm. Results expressed relative to vector controls. (K) Fluorescence microscopic images of lung metastases in mice injected by tail vein with green fluorescent protein–labeled (GFP-labeled) 393P cells transfected with anti-181b or anti-NC. Scatter plot: numbers of lung metastases per mouse (dots). Values are mean ± SD. n = 3, unless otherwise indicated. P values, 2-tailed Student’s t test and Dunnett’s test for 2-group comparisons and comparisons of more than 2 groups, respectively. Results were replicated (n ≥ 2 experiments). **P < 0.01 and ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts